TherapeuticsMD, Inc. Announces Milestone Achievement Of 50th Site For Phase 3 Clinical Trial Of TX 12-001HR To Treat Symptoms Of Menopause And Provide Endometrial Protection

Published: Jan 06, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company ("TherapeuticsMD" or the "Company"), announced today that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.

Help employers find you! Check out all the jobs and post your resume.

Back to news